State Street SPDR S&P Biotech ETF
125 hedge funds and large institutions have $1.05B invested in State Street SPDR S&P Biotech ETF in 2013 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 49 increasing their positions, 36 reducing their positions, and 12 closing their positions.
42% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 12
36% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 36
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
2% more funds holding
Funds holding: 123 → 125 (+2)
0% more capital invested
Capital invested by funds: $1.05B → $1.05B (+$2.03M)
14% less call options, than puts
Call options by funds: $15.5M | Put options by funds: $18M
76.23% less ownership
Funds ownership: 364.4% → 288.16% (-76%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$30.6M |
| 2 |
Barclays
London,
United Kingdom
|
+$12.2M |
| 3 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$11.5M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.59M |
| 5 |
LPL Financial
San Diego,
California
|
+$7.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$194M |
| 2 |
Citigroup
New York
|
-$66.4M |
| 3 |
MSA
Mason Street Advisors
Milwaukee,
Wisconsin
|
-$22.1M |
| 4 |
IG
ING Group
Amsterdam,
Netherlands
|
-$17.5M |
| 5 |
HF
Hoxton Financial
Shepherdstown,
West Virginia
|
-$7.57M |
XBI Hedge Fund Activity: Q3 2013 in Review
125 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q3 2013, worth a combined $1.05B — up 0.19% from $1.05B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new XBI positions and 12 closed out — a net gain of 5 holders — while 49 added to existing stakes and 36 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $30.6M. The largest seller was Deutsche Bank, cutting an estimated $194M.
- 125 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q3 2013, up from 123 in Q2 2013.
- Funds reported $1.05B of State Street SPDR S&P Biotech ETF stock for Q3 2013, up 0.19% quarter-over-quarter.
- 17 funds opened new State Street SPDR S&P Biotech ETF positions in Q3 2013 and 12 closed out, a net change of +5 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q3 2013 was JP Morgan Chase, an estimated $30.6M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q3 2013 was Deutsche Bank, an estimated $194M sold.
Based on aggregated 13F filings for Q3 2013.